Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 22 |
| Active Pipeline (Recruiting Now) | 5 (1) |
| Completed vs Stopped Early | 10 / 7 (31.8%) |
| Median Closed Actual Enrollment | 68 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| UCLA Health and Jonsson Comprehensive Cancer Center | Los Angeles, CA | 6 |
| Children's Hospital of Philadelphia | Philadelphia, PA | 6 |
| Stanford Health Care and Stanford Cancer Institute | Stanford, CA | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05099640 | A Study of PTC923 in Participants With Phenylketonuria | Phase III | COMPLETED |
| NCT05218655 | A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease | Phase III | COMPLETED |
| NCT05269355 | A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) | Phase II/III | TERMINATED |
| NCT05349721 | Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS | Phase II | TERMINATED |
| NCT03783923 | A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I) | Phase III | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the PTC Therapeutics Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.